PubMed Health⌕ Search

PubMed · 9319749

Amino acid sequence differences cannot fully explain interspecific variation in thermal sensitivities of gobiid fish A4-lactate dehydrogenases (A4-LDHs)

Abstract

We compared the deduced amino acid sequences, heat stabilities and thermal sensitivities of a kinetic property, the apparent Michaelis­Menten constant (Km) of pyruvate, of A4-lactate dehydrogenase (A4-LDH) in four species of goby fishes (Family Gobiidae), adapted to different temperatures, to examine how changes in primary structure influence the adaptation of enzymes. The effect of temperature on Km of pyruvate reflected each species' environmental temperature. For the most eurythermal species, Gillichthys seta, which is endemic to shallow intertidal regions of the upper Gulf of California and encounters temperatures between approximately 9 and 40 °C, Km of pyruvate was minimally affected by temperature, compared with the A4-LDH orthologues from a less eurythermal congener, G. mirabilis (9­30 °C), a cold temperate goby, Coryphopterus nicholsi (10­18 °C) and a tropical species, C. personatus (25­32 °C). Heat denaturation profiles failed to correlate with habitat temperature; G. mirabilis A4-LDH was most thermally stable, followed by the orthologues of C. nicholsi and G. seta. Complementary DNAs (cDNAs) encoding LDH-As of G. seta, Gulf of California and Pacific coast populations of G. mirabilis and C. nicholsi were isolated and sequenced, and the corresponding amino acid sequences deduced. The nucleotide sequences of LDH-A of the two populations of G. mirabilis were identical. Five nucleotide differences in the coding region and one amino acid substitution (at position 78) distinguished LDH-As of G. mirabilis and C. nicholsi. The substitution of a glycyl residue (C. nicholsi) for an alanyl residue (G. mirabilis) may account for the difference in thermal stability between these two orthologues. Comparisons of the LDH-A cDNAs of G. mirabilis and G. seta revealed four differences in nucleotide sequence in the coding region, but all nucleotide substitutions were synonymous. The identical deduced primary structures of the two enzymes suggested the possibility of different protein conformational variants ('conformers') in the two species. This hypothesis is supported by electrospray ionization mass spectrometry, which indicates that the masses of the A4-LDH orthologues of the two species are the same within the resolution of the technique. To explore the possibility that the two enzymes were different conformers of the same primary structure, we treated purified G. seta and G. mirabilis A4-LDHs with 3.0 mol l-1 urea or 6 mol l-1 guanidine­HCl and, after removing the denaturant, compared their kinetic properties and heat stabilities. Neither treatment had an effect on the A4-LDH of G. mirabilis, but both converted the Km versus temperature profile of the G. seta enzyme to that of the G. mirabilis A4-LDH. The thermal stability of neither enzyme was affected. We propose, as has been suggested in several previous studies of A4-LDH, that this enzyme can fold into a number of conformers with different stabilities and functional properties. The A4-LDH of G. seta furnishes evidence that such conformers may provide an important mechanism for adaptation of proteins to temperature.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P Fields, G Somero. 1997. Amino acid sequence differences cannot fully explain interspecific variation in thermal sensitivities of gobiid fish A4-lactate dehydrogenases (A4-LDHs). https://doi.org/10.1242/jeb.200.13.1839

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗